Muscular dystrophy is treated with a combination of medications to slow muscle loss, physical therapy to maintain function, assistive devices, heart monitoring, and in some cases gene therapy or surgery. There is no cure for any form of muscular dystrophy, but treatments have advanced significantly in the past decade, and the right combination can preserve strength, extend mobility, and improve quality of life for years longer than was possible a generation ago.
Because “muscular dystrophy” is actually a group of more than 30 genetic diseases, treatment varies depending on the specific type, a person’s age, and which muscles are most affected. Duchenne muscular dystrophy (DMD), the most common and severe childhood form, has the most developed treatment landscape, so much of the detail below centers on DMD while noting key differences for other types.
Corticosteroids: The Foundation Treatment
For decades, corticosteroids have been the backbone of DMD management. Prednisone and deflazacort both slow the rate of muscle breakdown by reducing inflammation. The preferred daily dose of prednisone is 0.75 mg/kg, which has been shown to improve muscle strength and lung function. Deflazacort, at a dose of about 0.9 mg/kg per day, may delay loss of the ability to walk by roughly 1.4 to 2.5 years compared to no treatment.
Corticosteroids also help protect the heart. Boys on either medication are less likely to develop the heart muscle weakness (cardiomyopathy) that commonly accompanies DMD, with studies suggesting a delay in onset through at least age 18. The trade-off is a real list of side effects: significant weight gain, increased body hair, a rounded “cushingoid” face, and weakened bones. If side effects become difficult to manage, lowering the prednisone dose to 0.3 mg/kg per day reduces those problems, though with somewhat less benefit to muscle strength.
A Nonsteroidal Alternative: Givinostat
In 2024, the FDA approved Duvyzat (givinostat) for patients with DMD aged six and older, making it the first nonsteroidal drug approved for all genetic variants of the disease. It works differently from steroids: rather than broadly suppressing inflammation, it targets specific processes that drive inflammation and muscle loss at the cellular level.
In clinical trials, patients treated with givinostat for 18 months showed significantly less decline in the time it took them to climb four stairs, worsening by an average of 1.25 seconds compared to 3.03 seconds in the placebo group. They also maintained better overall motor function scores. For families struggling with corticosteroid side effects, givinostat represents a meaningful new option.
Gene-Targeted Therapies
DMD is caused by mutations in the gene that makes dystrophin, a protein muscles need to stay intact. Two categories of treatment now target the genetic root of the disease directly.
Exon Skipping Drugs
These are precision medicines, each designed for a specific type of mutation. They work by instructing cells to skip over the faulty section of the gene so the body can produce a shorter but partially functional version of dystrophin. Four exon skipping drugs currently have FDA approval:
- Eteplirsen, which skips exon 51 (approved 2016)
- Golodirsen, which targets exon 53
- Viltolarsen, which also targets exon 53
- Casimersen, which targets exon 45
Together, these drugs address some of the most common DMD mutations, but they only work if a person’s specific deletion matches the targeted exon. Genetic testing is essential to determine eligibility. Each is given as a regular intravenous infusion.
Gene Therapy
Delandistrogene moxeparvovec (brand name Elevidys) is a one-time intravenous gene therapy approved for ambulatory patients with DMD aged four and older. It uses a harmless virus to deliver a shortened but functional version of the dystrophin gene directly into muscle cells. It is not suitable for patients with deletions in exons 8 or 9 of the dystrophin gene.
The therapy initially received broader approval, but after reports of fatal acute liver failure in two non-ambulatory patients, the FDA added a boxed warning and restricted the indication to patients who can still walk. Close liver monitoring before and after treatment is part of the protocol.
Heart Monitoring and Protection
Heart problems are one of the leading causes of serious complications in muscular dystrophy. In DMD, the same protein deficiency that weakens skeletal muscles also weakens the heart over time. Current guidelines recommend yearly cardiac screening starting at the time of diagnosis, a change from older recommendations that spaced screenings every two years before age 10.
Cardiac MRI is now the preferred imaging method because it can detect early damage to heart muscle tissue before the heart’s pumping ability visibly declines on a standard echocardiogram. When early signs of heart dysfunction appear, medications that reduce the workload on the heart (commonly ACE inhibitors or beta-blockers) are typically started to slow the progression. For patients who already have established heart abnormalities, visits may need to happen more frequently than once a year.
Physical Therapy and Exercise
Regular, gentle exercise is one of the most important ongoing treatments for muscular dystrophy. Submaximal exercise, meaning activity well below a person’s maximum effort, helps maintain existing muscle strength and prevents the additional weakness that comes simply from inactivity (disuse atrophy). Swimming, gentle cycling, and light resistance activities are common choices.
What to avoid matters just as much as what to do. High-resistance exercises and eccentric movements, where muscles are forced to lengthen under load (think lowering a heavy weight slowly, or walking downhill), can actively damage already-vulnerable muscle fibers and accelerate the disease. There are surprisingly few formal guidelines about exactly how much exercise is optimal, so the general principle is to stay active at a comfortable level without pushing into fatigue or soreness.
Stretching is a daily priority. As muscles weaken, they tend to shorten and tighten, pulling joints into fixed positions called contractures. Regular stretching of the calves, hamstrings, and hip flexors helps maintain range of motion and delays the point where contractures limit function.
Bracing, Orthotics, and Mobility Support
As leg muscles weaken, orthotic devices help maintain alignment and extend the period a person can stand and walk. Knee-ankle-foot orthoses (KAFOs) support the knee, ankle, and foot in proper alignment and have been shown to increase the length of time assisted walking and standing can continue. Hip-knee-ankle-foot orthoses (HKAFOs) extend that support to the hip for people who need full lower-limb stabilization.
Standing, even passively with support, provides benefits beyond mobility. It preserves muscle length and joint range of motion through sustained stretching of the hips and legs, helps maintain bone density (reducing fracture risk), can delay the onset of scoliosis, and supports better respiratory function. When standing in good alignment becomes difficult on its own, passive or motorized standing devices are recommended as long as contractures aren’t too severe to allow proper positioning.
Power wheelchairs eventually become necessary for most people with DMD, typically in the early teenage years. Modern chairs with tilt, recline, and elevating leg rests help manage comfort, pressure relief, and respiratory function throughout the day.
Respiratory Care
As the muscles responsible for breathing weaken, respiratory support becomes a central part of treatment. This usually progresses in stages. Early on, lung function is monitored regularly with breathing tests. When nighttime breathing becomes shallow, a bilevel positive airway pressure (BiPAP) machine helps push air into the lungs during sleep. Over time, some patients need ventilatory support during the day as well. Techniques like assisted coughing, either manually or with a mechanical cough-assist device, help clear mucus from the airways and prevent pneumonia.
Scoliosis and Surgical Options
Scoliosis, a sideways curvature of the spine, develops in most boys with DMD after they stop walking, because the trunk muscles can no longer hold the spine straight. Once the curve in the lower spine passes about 35 degrees, further progression is essentially inevitable without intervention. Spinal fusion surgery stabilizes the spine with metal rods, preventing the curve from worsening to the point where it compresses the lungs and restricts breathing.
Timing matters. Surgery is generally considered when lung capacity is still at 35% or more of the predicted normal value, because the procedure requires general anesthesia and adequate respiratory reserve for safe recovery. Waiting too long can mean the window for surgery closes. For patients who do undergo the procedure, the result is a straighter, more stable trunk that improves seated posture and comfort in a wheelchair.
Treating Myotonic Dystrophy
Myotonic dystrophy type 1, the most common adult-onset muscular dystrophy, presents a different set of challenges. The hallmark symptom, myotonia, is the inability to relax muscles after contracting them. This shows up as difficulty releasing your grip, trouble swallowing, or slurred speech. Mexiletine, a medication that calms overactive electrical signals in muscle fibers, is commonly used to manage these symptoms and has FDA orphan drug designation for myotonic dystrophy. While a clinical study showed improvements in grip strength, it did not meet its primary goal of improving walking distance, and larger trials are ongoing.
Myotonic dystrophy also affects the heart’s electrical system, causing rhythm abnormalities that require regular cardiac monitoring. It can cause excessive daytime sleepiness, cataracts, and insulin resistance, meaning management involves a team of specialists beyond just a neurologist.